Subscribe

What are you looking for?

Main Menu

明報新聞網

和黃醫藥與GSK達成KRAS-EGFR抗體偶聯癌症藥物獨家協議 股價勁彈16%

Future Wealths
Future Wealths
3 9 月, 2026
One Min Read
1 Views
0 Comments
和黃醫藥（0013）今日宣布與GSK plc（簡稱「葛蘭素史克」）附屬公司，就KRAS-EGFR抗體偶聯癌症藥物達成一項獨家開發及許可協議，消息刺激和黃醫藥午後股價最多勁彈逾16.5%見3個月高，暫報21.82元，漲14%，成交急增至4.76億元。

原文: https://finance.mingpao.com/fin/instantf/20260903/1788416612989/%E5%92%8C%E9%BB%83%E9%86%AB%E8%97%A5%E8%88%87gsk%E9%81%94%E6%88%90kras-egfr%E6%8A%97%E9%AB%94%E5%81%B6%E8%81%AF%E7%99%8C%E7%97%87%E8%97%A5%E7%89%A9%E7%8D%A8%E5%AE%B6%E5%8D%94%E8%AD%B0-%E8%82%A1%E5%83%B9%E5%8B%81%E5%BD%8816%22%20target=%22blank

Last Update: 3 9 月, 2026

Please share this article if you like it!

Link Copied!
Future Wealths
Written By

Future Wealths

Other Articles

Related Posts

Our site uses cookies. By using this site, you agree to the Privacy Policy and Terms of Use.

Accept